Calvo Gutierrez, J.Lopez-Medina, C.Abalos-Aguilera, M. C.Perez Jimenez, A. B.Ruiz-Vilchez, D.Pilar, F. U.Ortega Castro, R.Escudero Contreras, A.Collantes Estevez, E.2023-05-032023-05-032022-06-01Gutierrez JC, López-Medina C, Ábalos-Aguilera MC, Jiménez ABP, Ruíz-Vilchez D, Pilar FU, et al. AB1149 EVALUATION OF THE EFFICACY AND SAFETY OF THE SARS-COV-2 VACCINE IN PATIENTS WITH CHRONIC INFLAMMATORY DISEASES TREATED WITH BIOLOGICAL THERAPY. Annals Of The Rheumatic Diseases [Internet]. 23 de mayo de 2022;81(Suppl 1):1691.2-1692.0003-4967http://hdl.handle.net/10668/20109In the current situation of the SARS-CoV-2 pandemic, the Spanish Society of Rheumatology recommends vaccination of patients with chronic inflammatory diseases (CID) under treatment with biological DMARDs (bDMARDs). However, the data regarding the generation of protective antibody titers after mRNA vaccines in patients with CID is limited.enSARS-CoV-2mRNA vaccinesPandemicsRheumatologyUndertreatmentVaccinationAntirheumatic agentsconference outputopen accessAntirreumáticosPandemiasReumatologíaTratamiento insuficienteVacunas de ARNm10.1136/annrheumdis-2022-eular.39261468-2060https://ard.bmj.com/content/annrheumdis/81/Suppl_1/1691.2.full.pdf850279007088